March 8, 2008 -- Reports surfaced last week that the SFDA will become part of the Ministry of Health; US-traded China life sciences companies moved lower in price, partly because of WuXi PharmaTech, which reports in the coming week; American Oriental reported solid numbers for its Q4 but traded lower; Simcere moved up on good 2007 results; the Topsun-Bayer deal received a reprieve when Topsun extended the deadline to June 30, 2008; Hovione will pay more than 13 million euros ($19.5 million) to buy a 75% stake in Zhejiang Hisyn; Invida will buy the Asia Pacific operations of Valeant Pharma for $37.8 million; Pharmaxis is seeking to start a clinical trial in China of Bronchitol™, and safety issues were back in the headlines as the FDA and Baxter International found a contaminant in Baxter’s heparin. More details...
